Aureon Laboratories Announces Appointment of New Executive Vice President and CFO

Aureon Laboratories Announces Appointment of New Executive Vice President and CFO
Robert L. Van Nostrand brings over twenty years of financial and strategic management experience to key post at biotechnology company


YONKERS, N.Y., January 14, 2010 - Aureon Laboratories, Inc. today announced the appointment of Robert L. Van Nostrand as Executive Vice President and Chief Financial Officer. Mr. Van Nostrand brings to Aureon an extensive background in the financial and strategic management of healthcare companies. Most recently, he served as Executive Vice President and Chief Financial Officer at AGI Dermatics, Inc., where he helped oversee the company's successful acquisition by a Fortune 500 cosmetics company. Prior to his tenure at AGI Dermatics, Mr. Van Nostrand spent 21 years at OSI Pharmaceuticals, Inc., where he served as Senior Vice President, Chief Compliance Officer and Chief Financial Officer, among other positions. Mr. Van Nostrand remains an active board member for Metabolix, Inc., Achillion Pharmaceuticals, Inc. and is affiliated with numerous organizations including the Association of Biofinance Officers and the New York Biotechnology Association. Mr. Van Nostrand will assume responsibility for all financial aspects of the company's activities.

"Aureon Laboratories has developed an impressive line of innovative prognostic tools that help physicians and patients by providing objective molecular information about each patient's tumor," said Mr. Van Nostrand. "I'm excited to join the strong team at Aureon and look forward to playing an active role in the company's current and future expansion plans."

Prostate Px+, Aureon's lead product, is the only product of its kind in prostate cancer and helps newly diagnosed patients make more informed treatment decisions with its patented analysis of each patient's carcinoma specimen. Prostate Px+ successfully identifies patients with aggressive, life-threatening prostate cancer with greater accuracy than any other method currently available.

"Bob's experience in leading finance and business teams in the healthcare industry makes him a valuable addition to our team," said Robert Shovlin, President and CEO of Aureon Laboratories. "We're excited to be able to leverage Bob's extensive financial and strategic management expertise as we continue to expand and grow the company."

About Aureon Laboratories
Aureon Laboratories' mission is to enable personalized patient care through predictive pathology. Aureon has developed a high throughput systems pathology technology platform to predict individual clinical outcomes through the interrogation of tissue. The platform generates and analyzes an integrated, digital view of clinical findings, tissue micro-anatomy and tissue molecular pathology to determine which combination of features predicts specified individual clinical outcomes. Allied with major cancer centers, Aureon operates a CLIA-certified and CAP-accredited laboratory that provides predictive pathology services to the practicing physician. For more information about Aureon, please visit www.aureon.com or call 1-888-SYS-PATH.

 

####

Contact:
Aureon Laboratories
Jason Alter, Ph.D.
Phone: 914-377-4036
[email protected]
 


PRIVACY POLICY|COPYRIGHT 2010

Suggested Articles

Argenx’s phase 3 data set the bar for rival FcRn assets in development at Alexion, Immunovant and UCB.

Tufts scientists discovered that two anti-seizure drugs can lessen the development of brain defects caused by nicotine exposure in frogs.

Merck will apply its vaccine capabilities to an asset based on Themis’ measles vector platform that is set to enter the clinic this year.